Stock Research for ATOS

ATOS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ATOS Stock Chart & Research Data

The ATOS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATOS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ATOS Due diligence Resources & Stock Charts

The ATOS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ATOS Detailed Price Forecast - CNN Money CNN View ATOS Detailed Summary - Google Finance
Yahoo View ATOS Detailed Summary - Yahoo! Finance Zacks View ATOS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ATOS Trends & Analysis - Trade-Ideas Barrons View ATOS Major Holders - Barrons
NASDAQ View ATOS Call Transcripts - NASDAQ Seeking View ATOS Breaking News & Analysis - Seeking Alpha
Spotlight View ATOS Annual Report - CompanySpotlight.com OTC Report View ATOS OTC Short Report - OTCShortReport.com
TradeKing View ATOS Fundamentals - TradeKing Charts View ATOS SEC Filings - Bar Chart
WSJ View Historical Prices for ATOS - The WSJ Morningstar View Performance/Total Return for ATOS - Morningstar
MarketWatch View the Analyst Estimates for ATOS - MarketWatch CNBC View the Earnings History for ATOS - CNBC
StockMarketWatch View the ATOS Earnings - StockMarketWatch MacroAxis View ATOS Buy or Sell Recommendations - MacroAxis
Bullish View the ATOS Bullish Patterns - American Bulls Short Pains View ATOS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ATOS Stock Mentions - StockTwits PennyStocks View ATOS Stock Mentions - PennyStockTweets
Twitter View ATOS Stock Mentions - Twitter Invest Hub View ATOS Investment Forum News - Investor Hub
Yahoo View ATOS Stock Mentions - Yahoo! Message Board Seeking Alpha View ATOS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ATOS - SECform4.com Insider Cow View Insider Transactions for ATOS - Insider Cow
CNBC View ATOS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ATOS - OTC Markets
Yahoo View Insider Transactions for ATOS - Yahoo! Finance NASDAQ View Institutional Holdings for ATOS - NASDAQ


Stock Charts

FinViz View ATOS Stock Insight & Charts - FinViz.com StockCharts View ATOS Investment Charts - StockCharts.com
BarChart View ATOS Stock Overview & Charts - BarChart Trading View View ATOS User Generated Charts - Trading View




Latest Financial News for ATOS


Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Posted on Monday April 15, 2024

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines i


Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Posted on Thursday April 11, 2024

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical st


Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Posted on Tuesday April 09, 2024

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a cli


Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Posted on Monday April 01, 2024

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual MeetingEnded 2023 with $88.5 million of cash and cash equivalents and no debt SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and ful


Stock Market & Investing Books

Enter a stock symbol to view the stock details.